GlassScriptPhysician profile
Candy S Williams
NPI 1124483482
$21,644.00
in general payments reported to CMS, 2019-2025
41 companies · $7,098 in 2025
The $7,098 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,121 · 2022: $3,510 · 2023: $4,573 · 2024: $4,341 · 2025: $7,098.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Consulting Fee: $1,080 · Education: $156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,776.53 |
| Consulting Fee | $1,080.00 |
| Education | $156.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,122.39 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,627.95 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $2,138.98 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $2,013.09 | 2021-2025 | Tremfya, Stelara, Simponi |
| Madrigal Pharmaceuticals | $1,796.61 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $812.18 | 2022-2025 | Dupixent |
| Pfizer INC. | $753.81 | 2023-2025 | |
| Gilead Sciences, INC. | $713.05 | 2021-2025 | |
| Genzyme Corporation | $571.99 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $494.09 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $400.87 | 2024-2025 | Omvoh |
| Celgene Corporation | $395.21 | 2021-2024 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $386.09 | 2024-2025 | Iqirvo |
| Aimmune Therapeutics, INC. | $380.78 | 2024-2025 | Zenpep, Vowst |
| Janssen Scientific Affairs, LLC | $292.24 | 2021-2022 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $273.12 | 2021-2024 | Rebyota, Clenpiq |
| Ardelyx, INC. | $270.75 | 2022-2025 | Ibsrela |
| Daiichi Sankyo INC. | $254.11 | 2021-2024 | Injectafer |
| Intercept Pharmaceuticals, INC. | $250.84 | 2022-2024 | Ocaliva |
| Braintree Laboratories, INC. | $243.06 | 2021-2023 | Sutab |
| Merck Sharp & Dohme LLC | $226.19 | 2021-2024 | Dificid |
| Qol Medical, LLC | $176.86 | 2023-2025 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $142.72 | 2023-2025 | Linzess |
| Myriad Women'S Health, INC. | $118.20 | 2023 | Myrisk |
| Celltrion USA INC. | $107.49 | 2023-2025 | Vegzelma, Yuflyma, Zymfentra |
| Medtronic, INC. | $103.08 | 2022-2025 | Interstim |
| Nestle Healthcare Nutrition INC. | $87.54 | 2021-2023 | |
| Alnylam Pharmaceuticals INC. | $80.03 | 2022-2023 | Givlaari |
| Biocon Biologics INC | $62.01 | 2025 | Yesintek |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.29 | 2023-2024 | Cyltezo |
| Amgen INC. | $60.07 | 2022-2023 | Avsola, Amjevita |
| Organon LLC | $48.28 | 2022-2023 | Hadlima, Renflexis |
| Novo Nordisk INC | $43.18 | 2025 | Wegovy |
| Recordati_rare_diseases_inc. | $29.15 | 2023 | Panhematin |
| Sanofi-Aventis U.S. LLC | $17.13 | 2025 | |
| Mylan Institutional INC. | $16.92 | 2023 | Hulio |
| Pharmacosmos Therapeutics INC. | $16.26 | 2025 | Monoferric |
| Redhill Biopharma INC. | $16.24 | 2021 | |
| Axonics, INC. | $15.32 | 2024 | Axonics |
| Sandoz INC. | $14.07 | 2024 | Hyrimoz |
| Mallinckrodt Hospital Products INC. | $11.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Candy Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.